Sentence examples for more clinical efficacy from inspiring English sources

Administration of piperacillin/tazobactam by continuous infusion may have more clinical efficacy than administration by intermittent infusion for the treatment of nosocomial pneumonia.

These data suggest that ceftazidime administration by continuous infusion may have more clinical efficacy that intermittent infusion, in treatment of VAP caused by P. aeruginosa.

These data suggest that continuous infusion ceftazidime therapy may have more clinical efficacy and may be cheaper than intermittent bolus administration for the treatment of nosocomial pneumonia, but further larger studies are required to confirm it.

Our results suggest that administration of meropenem by CIA may have more clinical efficacy than administration by BII for the treatment of VAP, but more studies are required to confirm this.

Our data suggest that administration of meropenem by CI may have more clinical efficacy than administration by II for the treatment of nosocomial pneumonia, but more studies are required to confirm it.

Given the supportive and instructive role of the stroma in cancer progression, identifying therapeutics tailored to both the stroma and epithelium may have more clinical efficacy for prevention of local recurrence and prevention of metastases.

This is in contrast to the significant increase in proliferation and 600% increase in neurogenesis seen after ECT [16], and parallels the more robust clinical efficacy of ECT in treating depression compared to pharmacological agents such as fluoxetine [40].

It is possible that studies investigating longer treatment duration could have shown more pronounced clinical efficacy had these dose levels been well tolerated.

Our hope is that by characterizing the molecular basis for specific tumor endophenotypes in MPE, we will be able to better design rational therapeutic combinations that are more predictive of clinical efficacy.

23 Until there is more safety and clinical efficacy data, we cannot recommend the use of motavizumab.

There is therefore no evidence that laboratory studies which attempt to characterise specific aspects of antibacterial function in IVIG products would be more predictive of clinical efficacy than the existing clinical evidence from RCTs in support of non-specific, polyclonal IVIG therapy.